WT1 and acute myeloid leukemia: The group of Dr Felix Lichtenegger and Prof Marion Subklewe from Munich, Germany, used TLR-7/8-matured DCs loaded with WT1, PRAME and CMVpp65 mRNA in 10 AML patients who were in remission after intensive chemotherapy, but at high risk of relapse.